Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Biotricity expands reach with new GPO partnership

Published 2024-03-05, 08:40 a/m
© Reuters.
BTCY
-

REDWOOD CITY – Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, announced today its partnership with a top Group Purchasing Organization (GPO), significantly increasing its market access. This collaboration extends Biotricity's network to over 3,000 U.S. hospitals, which are part of a purchasing collective with more than $160 billion in buying power.

The company's latest alliance aims to strengthen its position in the healthcare sector, providing broader access to its technology and services. Biotricity's CEO, Waqaas Al-Siddiq, Ph.D., noted that the partnership is a testament to the company's commitment to delivering high-quality care and its growth potential.

GPOs are instrumental in the U.S. healthcare system, offering cost-effective procurement for medical facilities. They represent 97% of U.S. hospitals and negotiate favorable terms for medical supplies and devices, potentially saving the industry up to $55 billion annually according to the Healthcare Supply Chain Association.

Biotricity's new GPO affiliation is strategic as healthcare expenditures in the U.S. have reached $4.5 trillion in 2022, with an expected increase due to an aging population.

The company specializes in remote health monitoring solutions, focusing on cardiology and chronic care management. Biotricity emphasizes preventive and personal care through its diagnostic and post-diagnostic products for both medical and consumer markets.

This announcement is based on a press release statement.

InvestingPro Insights

Biotricity Inc.'s recent partnership with a top Group Purchasing Organization (GPO) positions it to leverage its expanded market access, as reflected in the company's strategic initiatives to penetrate the healthcare technology sector. The following insights from InvestingPro provide a snapshot of the company's current financial health and stock performance, which may be of interest to investors considering the potential impact of the GPO collaboration.

InvestingPro data indicates that Biotricity's market capitalization stands at $9.42 million, suggesting a relatively small but focused player within the medical technology space. Although the company has seen a robust revenue growth of 28.55% in the last twelve months as of Q3 2024, it faces challenges such as a negative P/E ratio of -0.57, signaling that the company is not currently profitable. The gross profit margin is strong at 65.52%, which may reflect well on the company's operational efficiency in generating revenue from its sales.

InvestingPro Tips highlight that Biotricity's short-term obligations exceed its liquid assets and analysts do not anticipate the company will be profitable this year. Furthermore, the stock price has experienced significant volatility, with a notable decline over the last year but showing a strong return over the last month. This could indicate a potential turnaround or a positive market reaction to recent developments, such as the GPO partnership.

For investors seeking more comprehensive analyses and additional InvestingPro Tips, there are 6 more tips available that could provide deeper insights into Biotricity's financial health and stock performance. To explore these tips and enhance your investment decisions, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

As Biotricity continues to expand its reach in the healthcare sector, these financial metrics and expert tips from InvestingPro may offer valuable context for stakeholders monitoring the company's progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.